Redmile Group, LLC Krystal Biotech, Inc. Transaction History

Redmile Group, LLC

$908 Million
Q3 2025

A detailed history of Redmile Group, LLC transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Redmile Group, LLC holds 661,388 shares of KRYS stock, worth $136 Million. This represents 12.86% of its overall portfolio holdings.

Number of Shares

661,388

Previous 663,471 0.31%

Holding current value

$136 Million

Previous $91.2 Million 28.02%

% of portfolio

12.86%

Previous 11.1%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	SELL	$134.94 - $176.75 $281,080 - $368,170	-2,083 Reduced 0.31%	661,388 $117 Million
Q2 2025 Aug 14, 2025	SELL	$123.36 - $181.0 $9.15 Million - $13.4 Million	-74,204 Reduced 10.06%	663,471 $91.2 Million
Q1 2025 May 15, 2025	SELL	$142.64 - $194.44 $2.21 Million - $3.01 Million	-15,500 Reduced 2.06%	737,675 $133 Million
Q4 2024 Feb 14, 2025	SELL	$156.64 - $199.61 $8.94 Million - $11.4 Million	-57,070 Reduced 7.04%	753,175 $118 Million
Q3 2024 Nov 14, 2024	SELL	$174.7 - $213.66 $36.8 Million - $45 Million	-210,833 Reduced 20.65%	810,245 $147 Million

Q2 2024 Aug 14, 2024	SELL	$153.12 - $183.64 $74.6 Million - $89.5 Million	-487,172 Reduced 32.3%	1,021,078 $188 Million
Q1 2024 May 15, 2024	SELL	$108.01 - $179.35 $24.3 Million - $40.3 Million	-224,939 Reduced 12.98%	1,508,250 $268 Million
Q4 2023 Feb 14, 2024	SELL	$96.0 - $128.29 $80 Million - $107 Million	-833,472 Reduced 32.47%	1,733,189 $215 Million
Q2 2023 Aug 14, 2023	BUY	$78.48 - $130.32 $51.3 Million - $85.1 Million	653,381 Added 34.15%	2,566,661 $301 Million
Q1 2023 May 15, 2023	BUY	$72.39 - $84.27 $1.2 Million - $1.4 Million	16,635 Added 0.88%	1,913,280 $153 Million
Q4 2022 Feb 14, 2023	SELL	$63.14 - $79.9 $183,106 - $231,710	-2,900 Reduced 0.15%	1,896,645 $150 Million
Q3 2022 Nov 14, 2022	BUY	$64.85 - $82.4 $64,849 - $82,400	1,000 Added 0.05%	1,899,545 $132 Million
Q2 2022 Aug 15, 2022	BUY	$48.93 - $73.47 $4.05 Million - $6.09 Million	82,847 Added 4.56%	1,898,545 $125 Million
Q1 2022 May 16, 2022	SELL	$51.99 - $72.11 $270,348 - $374,972	-5,200 Reduced 0.29%	1,815,698 $121 Million
Q4 2021 Feb 14, 2022	SELL	$39.81 - $88.24 $6.43 Million - $14.3 Million	-161,534 Reduced 8.15%	1,820,898 $127 Million
Q3 2021 Nov 15, 2021	SELL	$52.01 - $71.77 $4.67 Million - $6.44 Million	-89,700 Reduced 4.33%	1,982,432 $104 Million
Q2 2021 Aug 16, 2021	BUY	$62.14 - $81.82 $745,680 - $981,839	12,000 Added 0.58%	2,072,132 $141 Million
Q1 2021 May 17, 2021	BUY	$59.42 - $85.46 $22.9 Million - $32.9 Million	385,096 Added 22.99%	2,060,132 $159 Million
Q4 2020 Feb 16, 2021	BUY	$40.64 - $61.38 $7.03 Million - $10.6 Million	173,091 Added 11.52%	1,675,036 $101 Million
Q3 2020 Nov 16, 2020	BUY	$37.76 - $48.49 $3.48 Million - $4.47 Million	92,200 Added 6.54%	1,501,945 $64.7 Million
Q2 2020 Aug 14, 2020	BUY	$37.03 - $60.0 $13.3 Million - $21.5 Million	357,945 Added 34.03%	1,409,745 $58.4 Million
Q1 2020 May 15, 2020	SELL	$35.02 - $65.64 $1.34 Million - $2.52 Million	-38,400 Reduced 3.52%	1,051,800 $45.5 Million
Q4 2019 Feb 14, 2020	BUY	$33.17 - $65.23 $394,723 - $776,237	11,900 Added 1.1%	1,090,200 $60.4 Million
Q3 2019 Nov 14, 2019	SELL	$34.72 - $51.3 $69,440 - $102,600	-2,000 Reduced 0.19%	1,078,300 $37.4 Million
Q2 2019 Aug 14, 2019	BUY	$27.2 - $41.2 $20.6 Million - $31.1 Million	755,800 Added 232.91%	1,080,300 $43.5 Million
Q1 2019 May 15, 2019	SELL	$19.86 - $32.9 $9,930 - $16,450	-500 Reduced 0.15%	324,500 $10.7 Million
Q4 2018 Feb 14, 2019	BUY	$15.03 - $25.38 $4.88 Million - $8.25 Million	325,000 New	325,000 $6.75 Million

Others Institutions Holding KRYS

# of Institutions

325

Shares Held

25M

Call Options Held

241K

Put Options Held

625K

View Full List

About Krystal Biotech, Inc.

Ticker KRYS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,664,300
Market Cap $5.29B
Description
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...

More about KRYS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Redmile Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Redmile Group, LLC with notifications on news.

Account

Redmile Group, LLC Krystal Biotech, Inc. Transaction History